

Supporting Information

Base-Mediated Ketenimine Formation from *N*-Sulfonylthioimidates for the Synthesis of 5-Amino-1-Vinyl/Aryl-1,2,3-Triazoles

Wan-Yu Chen, Wei-Han Lin, Chia-Jou, Kuo, Chien-Fu Liang*

Department of Chemistry, National Chung Hsing University, Taichung 402, Taiwan

E-mail: lcf0201@dragon.nchu.edu.tw

Table of contents

1. General Information.....	S2
2. Optimized Conditions.....	S3
3. General Procedure.....	S4
4. X-ray Data and Characterization Data of compounds 3aa and 6	S6
4. Characterization Data.....	S8
5. References.....	S40
6. Copies of ^1H and ^{13}C NMR Spectra of products.....	S41


General information

All reactions were performed under nitrogen atmosphere. ^1H NMR and ^{13}C NMR spectra were reported on Varian 400 MHz and Jeol 400 MHz NMR spectrometer with CDCl_3 、 CD_3OD 、 $d_6\text{-DMSO}$ 、 $d_6\text{-acetone}$ as the solvent. Chemical shifts were reported in parts per million (ppm) relative to residual solvent peak ($\text{CDCl}_3 \delta \text{ H} = 7.26 \text{ ppm}$, $\delta \text{ C} = 77.16 \text{ ppm}$; $\text{CD}_3\text{OD} \delta \text{ H} = 3.31 \text{ ppm}$, $\delta \text{ C} = 49.15 \text{ ppm}$; $d_6\text{-DMSO} \delta \text{ H} = 2.49 \text{ ppm}$, $\delta \text{ C} = 39.15 \text{ ppm}$; $d_6\text{-Acetone} \delta \text{ H} = 2.05 \text{ ppm}$, $\delta \text{ C} = 29.92 \text{ ppm}$) and were used as internal standard, α,α,α -trifluorotoluene in deuteron benzene ($\delta \text{ -63.9 ppm}$ in ^{19}F NMR).

The IR spectra were measured on a Thermo Scientific Nicolet ATR-Diamond. Thin layer chromatography (TLC) was performed on pre-coated glass plates of Silica Gel 60 F₂₅₄ (0.25 mm, E. Merck); TLC plates were visualized under UV light (254 or 365 nm) and by treatment with potassium permanganate (KMnO_4) or phosphomolybdic acid staining solution followed by heating. Flash column chromatography was carried out by using Silica Gel 60 (230–400 mesh, E. Merck). High resolution mass spectrometry (HRMS) data were recorded on an EI spectrometer. Melting points were measured by Electrothermo (UK) “Mel- emp” type melting point apparatus and are uncorrected. The following abbreviations were used to indicate splitting patterns of multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, quin. = quintet, sext = sextet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, ddd = doublet of doublet of doublets, brs = broad single, m = multiplet. Coupling constants (J) are reported in Hz.

Yields of products refer to chromatographically purified products unless otherwise stated. All terminal alkyne and thiol reagents were purchase from Sigma Aldrich, Alfa Aesar, Merck, or TCI. The compounds **1a'** and **1a''** were prepared by our previous work.¹ All vinyl azides (**2a-2i**)² and aryl azides (**4a-4i**)³ were known compounds and synthesized by reported methods.²⁻³ All these compounds were used as received, unless otherwise stated.

Table S1. Optimized Conditions



entry	2a (equiv)	base	solvent	time(h)	temp (°C)	yield ^a
1	2	DBU	THF	12	50	33%
2	2	DBU	ACN	12	50	31%
3	2	DBU	1,4-Dioxane	12	50	25%
4	2	DBU	Toluene	12	50	23%
5	2	DBU	DMF	12	50	44%
6	2	DBU	DMF	6	50	50%
7	2	—	DMF	12	50	— ^b
8	3	DBU	DMF	6	50	60%
9	3	K ₂ CO ₃	DMF	6	50	55%
10	3	Cs ₂ CO ₃	DMF	6	50	62%
11	3	K ₃ PO ₄	DMF	6	50	66%
12	3	K ₃ PO ₄	DMSO	6	50	73%
13	3	K ₃ PO ₄	DMSO	6	80	80%
14	3	K ₃ PO ₄	DMSO	6	90	78%
15	1.5	K ₃ PO ₄	DMSO	6	80	40%
16	3	K ₃ PO ₄	DMSO	6	80	47% ^c
17	3	K ₃ PO ₄	DMSO	6	80	85% ^d
18	3	K ₃ PO ₄	DMSO	6	80	58% ^e

Reaction conditions: **1a'** (1.0 equiv), **2a**, and base (2.0 equiv) under nitrogen atmosphere. ^a Isolated yield. ^b No desired product formation, only starting material **1a'** was recovered. ^c K₃PO₄ was used 1.5 equiv in reaction conditions. ^d Use of **1a** as substrate (R = OMe). ^e Use of **1a''** as substrate (R = Cl)

General Procedure I: For N-sulfonylthioimide (1**) synthesis¹**

To a solution of phenyl acetylene (50.0 mg, 0.489 mmol, 1.0 equiv) in DCM (1.6 mL) was added *p*-toluenesulfonyl azide (116.0 mg, 0.587 mmol, 1.2 equiv), DMAP (60.0 mg, 0.489 mmol, 1.0 equiv) and CuI (19.0 mg, 0.098 mmol, 0.2 equiv). The resulting solution was stirred at room temperature under nitrogen atmosphere for 1 h. Then 4-methoxybenzyl thiol (227.0 mg, 1.467 mmol, 3.0 equiv) was added to the reaction mixture and stirred for several hours until the reaction was complete as indicated by TLC. The mixture was extracted with DCM for three times and the combined organic phase was washed with brine, dried over MgSO₄, filtered and concentrated. The crude products were purified by flash column chromatography to afford the desired product **1a** (153.8 mg, 74%) as a yellow solid. The products of **1b-1l** were synthesized by following general procedure I

General Procedure II: For 5-amino-1-vinyl-1,2,3-triazole (3**) synthesis**

To a solution of thioimide **1a** (50.0 mg, 0.117 mmol, 1 equiv) and potassium phosphate (51.0 mg, 0.235 mmol, 2 equiv) in DMSO (0.39 mL) was added vinyl azide **2a** (51.0 mg, 0.351 mmol, 3 equiv), the resulting reaction mixture was stirred at 80 °C under nitrogen atmosphere for several hours until the reaction was completed as indicated by TLC. The mixture was extracted with DCM for three times and the combined organic phase was washed with 2N HCl solution and brine, dried over MgSO₄, filtered and concentrated. The crude product was purified by flash column chromatography to afford the desired products **3aa** (41.4 mg, 85%) as a white solid. The products of **3ba-3la**, **3ab-3ai**, **3cb-3cc**, and **3hb-3hc** were synthesized by following general procedure II.


General Procedure III: For 5-amino-1-aryl-1,2,3-triazole (5) synthesis

To a solution of *N*-sulfonylthioimidate **1a'** (100.0 mg, 0.253 mmol, 1 equiv) and potassium phosphate (107.4 mg, 0.506 mmol, 2 equiv) in DMSO (0.84 mL) was added azidobenzene **4a** (90.3 mg, 0.759 mmol, 3 equiv), the resulting reaction mixture was stirred at 80 °C under nitrogen atmosphere for 8 hours until the reaction was completed as indicated by TLC. The mixture was extracted with DCM for three times and the combined organic phase was washed with 2N HCl solution and brine, dried over MgSO₄, filtered and concentrated. The crude product were purified by flash column chromatography to afford the desired products **5aa** (69.2 mg, 70%) as a white solid. The products of **5ab-5ai** were synthesized by following general procedure III.

X-ray Crystallographic Studies and the X-ray Data of 3aa and 6

Single crystals of compounds **3aa** and **6** suitable for X-ray diffraction measurements were mounted on the Bruker D8 VENTURE and the unit cell was determined using Bruker SMART APEX 3 software suite to employ graphite-monochromated Mo-K α radiation ($\lambda = 0.71073 \text{ \AA}$), and intensity data were collected with ω scans. The data collection and reduction were performed with the CrysAlisPro software, and the absorptions were corrected by the SCALE3 ABSPACK multiscan method. The space-group determination was based on a check of the Laue symmetry and systematic absences, and it was confirmed using the structure solution. The structure was solved and refined with the Olex2 1.2-ac21 package. Anisotropic thermal parameters were used for all non-H atoms, and fixed isotropic parameters were used for H atoms. CCDC numbers of 2216076 for compound **3aa** and 2201717 for compound **6** contain the supplementary crystallographic data for this paper, respectively. Both of the checkCIF reports are given below:

For compound 3aa, CCDC No: 2216076



Datablock: mo_cjk_b023_0m_pl

Bond precision: C-C = 0.0053 Å Wavelength=0.71076

Cell: $a=11.4274(6)$ $b=25.1111(16)$ $c=14.2863(10)$
 $\alpha=90$ $\beta=91.378(2)$ $\gamma=90$

Temperature: 150 K


	Calculated	Reported
Volume	4098.3(4)	4098.3(4)
Space group	P 21/c	P 1 21/c 1
Hall group	-P 2ybc	-P 2ybc
Moiety formula	C23 H20 N4 O2 S	2(C23 H20 N4 O2 S)
Sum formula	C23 H20 N4 O2 S	C46 H40 N8 O4 S2
Mr	416.49	832.98
Dx, g cm ⁻³	1.350	1.350
Z	8	4
μ (mm ⁻¹)	0.186	0.186
F000	1744.0	1744.0
F000'	1745.63	
h, k, lmax	14, 31, 17	14, 31, 17
Nref	8410	8390
Tmin, Tmax		0.706, 0.745
Tmin'		

Correction method= # Reported T Limits: Tmin=0.706 Tmax=0.745
AbsCorr = NONE

Data completeness= 0.998 Theta(max)= 26.404

R(reflections)= 0.0570(5598) wR2(reflections)=
0.2077(8390)
S = 1.215 Npar= 543

For compound 6, CCDC No: 2201719



Datablock: mo_cwy_3023_pl

Bond precision: C-C = 0.0097 Å Wavelength=0.71076


Cell: $a=14.496(2)$ $b=11.4484(18)$ $c=25.707(5)$
 $\alpha=90$ $\beta=90$ $\gamma=90$

Temperature: 150 K

	Calculated	Reported
Volume	4266.2(12)	4266.2(12)
Space group	P b c a	P b c a
Hall group	-P 2ac 2ab	-P 2ac 2ab
Moiety formula	C23 H22 N4 O2 S	C23 H22 N4 O2 S
Sum formula	C23 H22 N4 O2 S	C23 H22 N4 O2 S
Mr	418.51	418.50
Dx, g cm ⁻³	1.303	1.303
Z	8	8
μ (mm ⁻¹)	0.179	0.179
F000	1760.0	1760.0
F000'	1761.63	
h, k, lmax	17, 13, 30	17, 13, 30
Nref	3753	3669
Tmin, Tmax		
Tmin'		
Correction method	= Not given	
Data completeness	= 0.978	Theta (max) = 24.995
R(reflections)	= 0.0980(2275)	wR2(reflections) = 0.2433(3669)
S	= 1.007	Npar= 273


Characterization Data:

4-Methoxybenzyl (*E*)-2-phenyl-N-tosylethanimidothioate (**1a**)¹



Following the General Procedure I, using phenylacetylene (50.0 mg, 0.489 mmol), tosyl azide (116 mg, 0.587 mmol) and 4-methoxybenzylthiol (227.0 mg, 1.469 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1a** (153.8 mg, 74% yield) as a yellow solid ; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, *J*=8.2 Hz, 2H), 7.35-7.31 (m, 7H), 7.00 (d, *J*=8.6 Hz, 2H), 6.71 (d, *J*=8.6 Hz, 2H), 4.45 (s, 2H), 3.95 (s, 2H), 3.76 (s, 3H), 2.46 (s, 3H) ; ¹³C NMR (100 MHz, CDCl₃) δ 188.8 (C), 159.1 (C), 143.7 (C), 138.7 (C), 133.9 (C), 130.4 (CH×3), 129.6 (CH×2), 128.7 (CH×2), 127.8 (CH×2), 127.2 (CH×2), 127.1 (C), 114.0 (CH×2), 55.3 (CH₃), 44.3 (CH₂), 36.0 (CH₂), 21.7 (CH₃).


4-Methoxybenzyl (*E*)-2-(4-methoxyphenyl)-N-tosylethanimidothioate (**1b**)



Following the General Procedure I, using 1-ethynyl-4-methoxybenzene (50.0 mg, 0.378 mmol), tosyl azide (90.0 mg, 0.454 mmol) and 4-methoxybenzylthiol (175.0 mg, 1.134 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1b** (99.7 mg, 58% yield) as a white solid. m.p. 119-120 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (d, *J*=8.2 Hz, 2H), 7.35 (d, *J*=8.2 Hz, 2H), 7.24 (d, *J*=8.6 Hz, 2H), 7.00 (d, *J*=8.6 Hz, 2H), 6.86 (d, *J*=8.6 Hz, 2H), 6.71 (d, *J*=8.6 Hz, 2H), 4.38 (s, 2H), 3.93 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H), 2.46 (s, 3H) ; ¹³C NMR (100 MHz,


CDCl_3 δ 189.8 (C), 159.3 (C), 159.0 (C), 143.6 (C), 138.8 (C), 131.6 ($\text{CH} \times 2$), 130.4 ($\text{CH} \times 2$), 129.6 ($\text{CH} \times 2$), 127.1 ($\text{CH} \times 2$, C), 125.8 (C), 114.1 ($\text{CH} \times 2$), 114.0 ($\text{CH} \times 2$), 55.3 ($\text{CH}_3 \times 2$), 43.6, (CH_2) 36.1(CH_2), 21.7 (CH_3); IR (ATR) ν 2971, 2935, 2842, 1561, 1509, 1471, 1441, 1289, 1249, 1151, 1087, 1029 ; HRMS (EI) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{24}\text{H}_{25}\text{NO}_4\text{S}_2$: 455.1225, found: 455.1234.

4-Methoxybenzyl (*E*)-2-(*p*-tolyl)-*N*-tosylethanimidothioate (1c)




Following the General Procedure I, using 1-ethynyl-4-methylbenzene (50.0 mg, 0.430 mmol), tosyl azide (102.0 mg, 0.517 mmol) and 4-methoxybenzylthiol (199.0 mg, 1.291 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1c** (98.2 mg, 52% yield) as a white solid. m.p. 108-110 °C ; ^1H NMR (400 MHz, CDCl_3) δ 7.86 (d, $J = 8.1$ Hz, 2H), 7.34 (d, $J = 8.2$ Hz, 2H), 7.20 (d, $J = 7.8$ Hz, 2H), 7.13 (d, $J = 8.1$ Hz, 2H), 7.00 (d, $J = 8.6$ Hz, 2H), 6.70 (d, $J = 8.6$ Hz, 2H), 4.40 (s, 2H), 3.93 (s, 2H), 3.75 (s, 3H), 2.45 (s, 3H), 2.33 (s, 3H) ; ^{13}C NMR (100 MHz, CDCl_3) δ 189.5 (C), 159.1 (C), 143.6 (C), 138.8 (C), 137.7 (C), 130.8 (C), 130.4 ($\text{CH} \times 2$), 130.3 ($\text{CH} \times 2$), 129.6 ($\text{CH} \times 2$), 129.4 ($\text{CH} \times 2$), 127.2 ($\text{CH} \times 2$, C), 114.0 ($\text{CH} \times 2$), 55.3 (CH_3), 44.0 (CH_2), 36.0 (CH_2), 21.7 (CH_3), 21.3 (CH_3) ; IR (ATR) ν 3000, 2981, 2911, 1607, 1532, 1505, 1310, 1287, 1236, 1149, 1088, 1032 ; HRMS (EI) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{24}\text{H}_{25}\text{NO}_3\text{S}_2$: 439.1276, found: 439.1268.

4-Methoxybenzyl (*E*)-2-(3-methoxyphenyl)-*N*-tosylethanimidothioate (1d)



Following the General Procedure I, using 1-ethynyl-3-methoxybenzene (50.0 mg, 0.378 mmol), tosyl azide (90.0 mg, 0.454 mmol) and 4-methoxybenzylthiol (175.0 mg, 1.135 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1d** (103.0 mg, 60% yield) as a white solid. m.p. 76-77 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, *J* = 8.3 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.24 (t, *J* = 7.8 Hz, 1H), 7.00 (d, *J* = 8.7 Hz, 2H), 6.90 (d, *J* = 7.6 Hz, 1H), 6.86-6.82 (m, 2H), 6.71 (d, *J* = 8.7 Hz, 2H), 4.40 (s, 2H), 3.95 (s, 2H), 3.78 (s, 3H), 3.76 (s, 3H), 2.46 (2, 3H) ; ¹³C NMR (100 MHz, CDCl₃) δ 188.3 (C), 159.6 (C), 158.9 (C), 143.5 (C), 138.5 (C), 135.1 (C), 130.2 (CH×2), 129.5 (CH), 129.4 (CH×2), 126.9 (CH×2, C), 122.5 (CH), 115.5 (CH), 113.8 (CH×2), 113.3 (CH), 55.1 (CH₃×2), 44.1 (CH₂), 35.6 (CH₂), 21.5 (CH₃) ; IR (ATR) ν 2964, 2912, 2841, 1610, 1583, 1552, 1511, 1488, 1313, 1265, 1247, 1154, 1079, 1047, 1029 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₄H₂₅NO₄S₂: 455.1225, found: 455.1217


4-Methoxybenzyl (*E*)-2-(naphthalen-2-yl)-*N*-tosylethanimidothioate (1e)



Following the General Procedure I, using 2-ethynlynaphthalene (50.0 mg, 0.328 mmol), tosyl azide (78.0 mg, 0.394 mmol) and 4-methoxybenzylthiol (152.0 mg, 0.986 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1e** (93.5 mg, 60% yield) as a white solid. m.p. 104-106 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.89 (d, *J* = 8.2 Hz, 2H), 7.83-7.77 (m, 3H), 7.74 (s, 1H), 7.49-7.46 (m, 2H), 7.43 (dd,


J = 8.4, 1.2 Hz, 1H), 7.33 (d, *J* = 8.1 Hz, 2H), 7.00 (d, *J* = 8.6 Hz, 2H), 6.70 (d, *J* = 8.6 Hz, 2H), 4.61 (s, 2H), 3.96 (s, 2H), 3.75 (2, 3H), 2.45 (s, 3H) ; ^{13}C NMR (100 MHz, CDCl_3) δ 188.8 (C), 159.1 (C), 143.7 (C), 138.6 (C), 133.4 (C), 132.8 (C), 131.3 (C), 130.4 ($\text{CH} \times 2$), 129.6 ($\text{CH} \times 2$), 129.4 (CH), 128.4 (CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 127.2 ($\text{CH} \times 2$), 127.1 (C), 126.4 (CH), 126.3 (CH), 114.0 ($\text{CH} \times 2$), 55.3 (CH_3), 44.4 (CH_2), 36.1 (CH_2), 21.7 (CH_3) ; IR (ATR) ν 3234, 3058, 2911, 1722, 1550, 1510, 1440, 1300, 1245, 1157, 1081, 1034; HRMS (EI) m/z : [M+H] $^+$ calcd. for $\text{C}_{27}\text{H}_{25}\text{NO}_3\text{S}_2$: 475.1276, found: 475.1270

4-Methylbenzyl (*E*)-3,3-dimethyl-N-tosylbutanimidothioate (1f)¹




Following the General Procedure I, using 3,3-dimethylbut-1-yne (300.0 mg, 3.652 mmol), tosyl azide (864.0 mg, 4.382 mmol) and *p*-tolylmethanethiol (1515.0 mg, 10.956 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1f** (298.4 mg, 21% yield) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.84 (d, *J* = 8.3 Hz, 2H), 7.31 (d, *J* = 8.3 Hz, 2H), 7.00 (s, 4H), 4.05 (s, 2H), 3.10 (s, 2H), 2.45 (s, 3H), 2.30 (s, 3H), 1.14 (s, 9H) ; ^{13}C NMR (100 MHz, CDCl_3) δ 187.3 (C), 143.4 (C), 139.1 (C), 137.3 (C), 132.6 (C), 129.5 ($\text{CH} \times 2$), 129.3 ($\text{CH} \times 2$), 128.9 ($\text{CH} \times 2$), 127.1 ($\text{CH} \times 2$), 50.3 (CH_2), 36.1 (CH_2), 32.5 (C), 30.5 ($\text{CH}_3 \times 3$), 21.7 (CH_3), 21.2 (CH_3).

4-Methoxybenzyl (*E*)-2-(4-nitrophenyl)-N-tosylethananimidothioate (1g)



Following the General Procedure I, using 1-ethynyl-4-nitrobenzene (50.0 mg, 0.340 mmol), tosyl azide (80.0 mg, 0.408 mmol) and 4-methoxybenzylthiol (157.0 mg, 1.020 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1g** (86.3 mg, 54% yield) as an orange solid. m.p. 110-111 °C ; ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.6 Hz, 2H), 7.85 (d, *J* = 8.3 Hz, 2H), 7.52 (d, *J* = 8.6 Hz, 2H), 7.35 (d, *J* = 8.2 Hz, 2H), 7.00 (d, *J* = 8.6 Hz, 2H), 6.72 (d, *J* = 8.6 Hz, 2H), 4.53 (s, 2H), 3.99 (s, 2H), 3.76 (s, 3H), 2.46 (s, 3H) ; ¹³C NMR (100 MHz, CDCl₃) δ 185.4 (C), 159.2 (C), 147.5 (C), 144.1 (C), 141.5 (C), 138.2 (C), 131.0 (CH×2), 130.4 (CH×2), 129.7 (CH×2), 127.2 (CH×2), 126.6 (C), 123.9 (CH×2), 114.1 (CH×2), 55.4 (CH₃), 43.7 (CH₂), 36.2 (CH₂), 21.7 (CH₃) ; IR (ATR) ν 2926, 2855, 1557, 1343, 1316, 1243, 1149, 1086, 1032 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₂₂N₂O₅S₂: 470.0970, found: 470.0979.


4-Methoxybenzyl (*E*)-2-(4-chlorophenyl)-N-tosylethanimidothioate (1h)



Following the General Procedure I, using 1-chloro-4-ethynylbenzene (50.0 mg, 0.366 mmol), tosyl azide (87.0 mg, 0.439 mmol) and 4-methoxybenzylthiol (169.0 mg, 1.098 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1h** (102.5 mg, 61% yield) as a white solid. m.p. 111-113 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, *J* = 8.3 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.30-7.24 (m, 4H), 7.00 (d, *J* = 8.8 Hz, 2H), 6.72 (d, *J* = 8.7 Hz, 2H), 4.40 (s, 2H), 3.95 (s, 2H), 3.76 (s, 3H), 2.46 (s, 3H) ; ¹³C NMR (100 MHz, CDCl₃) δ 187.7 (C), 159.1 (C), 143.7 (C), 138.4 (C), 133.8 (C), 132.4 (C), 131.6 (CH×2), 130.3 (CH×2), 129.5 (CH×2), 128.8 (CH×2), 127.1 (CH×2), 126.9 (C), 114.0 (CH×2), 55.3 (CH₃), 43.5 (CH₂), 36.0 (CH₂), 21.7


(CH₃) ; IR (ATR) ν 2914, 2838, 1607, 1537, 1508, 1312, 1238, 1151, 1088, 1033, 1017; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₂₂ClNO₃S₂: 459.0730, found: 459.0735

4-Methoxybenzyl (*E*)-2-(4-acetylphenyl)-N-tosylethanimidothioate (1i)



Following the General Procedure I, using 1-(4-ethynylphenyl)ethan-1-one (50.0 mg, 0.347 mmol), tosyl azide (82.0 mg, 0.416 mmol) and 4-methoxybenzylthiol (160.0 mg, 1.040 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1i** (105.3 mg, 65% yield) as a yellow solid. m.p. 112-114 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.92 (d, *J* = 8.2 Hz, 2H), 7.86 (d, *J* = 8.3 Hz, 2H), 7.44 (d, *J* = 8.2 Hz, 2H), 7.35 (d, *J* = 8.1 Hz, 2H), 7.00 (d, *J* = 8.6 Hz, 2H), 6.71 (d, *J* = 8.7 Hz, 2H), 4.49 (s, 2H), 3.96 (s, 2H), 3.76 (s, 3H), 2.59 (s, 3H), 2.46 (s, 3H) ; ¹³C NMR (100 MHz, CDCl₃) δ 197.8 (C), 186.9 (C), 159.1 (C), 143.9 (C), 139.3 (C), 138.4 (C), 136.5 (C), 130.5 (CH×2), 130.4 (CH×2), 129.6 (CH×2), 128.8 (CH×2), 127.2 (CH×2), 126.8 (C), 114.1 (CH×2), 55.3 (CH₃), 44.1 (CH₂), 36.1 (CH₂), 26.8 (CH₃), 21.7 (CH₃) ; IR (ATR) ν 3034, 2995, 2926, 1683, 1607, 1561, 1512, 1413, 1312, 1252, 1086, 1041, 1021 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₅H₂₅NO₄S₂: 467.1225, found: 467.1226


4-Methoxybenzyl (*E*)-2-(2-bromophenyl)-N-tosylethanimidothioate (1j)



Following the General Procedure I, using 1-bromo-2-ethynylbenzene (50.0 mg, 0.276 mmol), tosyl azide (65.0 mg, 0.331 mmol) and 4-methoxybenzylthiol (128.0 mg, 0.829 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1j** (80.0 mg, 62% yield) as a yellow solid. m.p. 112-114 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.92 (d, *J* = 8.2 Hz, 2H), 7.86 (d, *J* = 8.3 Hz, 2H), 7.44 (d, *J* = 8.2 Hz, 2H), 7.35 (d, *J* = 8.1 Hz, 2H), 7.00 (d, *J* = 8.6 Hz, 2H), 6.71 (d, *J* = 8.7 Hz, 2H), 4.49 (s, 2H), 3.96 (s, 2H), 3.76 (s, 3H), 2.59 (s, 3H), 2.46 (s, 3H) ; ¹³C NMR (100 MHz, CDCl₃) δ 197.8 (C), 186.9 (C), 159.1 (C), 143.9 (C), 139.3 (C), 138.4 (C), 136.5 (C), 130.5 (CH×2), 130.4 (CH×2), 129.6 (CH×2), 128.8 (CH×2), 127.2 (CH×2), 126.8 (C), 114.1 (CH×2), 55.3 (CH₃), 44.1 (CH₂), 36.1 (CH₂), 26.8 (CH₃), 21.7 (CH₃) ; IR (ATR) ν 3034, 2995, 2926, 1683, 1607, 1561, 1512, 1413, 1312, 1252, 1086, 1041, 1021 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₅H₂₅BrNO₄S₂: 482.1375, found: 482.1375


mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1j** (80.5 mg, 58% yield) as a white solid. m.p. 89-91 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, *J* = 8.2 Hz, 2H), 7.57 (d, *J* = 8.0 Hz, 1H), 7.38 (d, *J* = 8.1 Hz, 2H), 7.33-7.28 (m, 2H), 7.21 (td, *J* = 7.8, 1.8 Hz, 1H), 7.05 (d, *J* = 8.6 Hz, 2H), 6.74 (d, *J* = 8.6 Hz, 2H), 4.60 (s, 2H), 4.00 (s, 2H), 3.77 (s, 3H), 2.48 (s, 3H) ; ¹³C NMR (100 MHz, CDCl₃) δ 188.0 (C), 159.0 (C), 143.7 (C), 138.4 (C), 133.8 (C), 133.0 (CH), 132.5 (CH), 130.3 (CH×2), 129.7 (CH), 129.5 (CH×2), 127.6 (CH), 127.2 (CH×2), 126.9 (C), 126.0 (C), 113.9 (CH×2), 55.2 (CH₃), 44.9 (CH₂), 35.9 (CH₂), 21.7 (CH₃) ; IR (ATR) ν 2934, 2836, 1543, 1511, 1319, 1303, 1248, 1152, 1087, 1028 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₂₂BrNO₃S₂: 503.0224, found: 503.0221

4-Methoxybenzyl (*E*)-2-(4-bromophenyl)-N-tosylethanimidothioate (1k)




Following the General Procedure I, using 1-bromo-4-ethynylbenzene (50.0 mg, 0.276 mmol), tosyl azide (65.0 mg, 0.331 mmol) and 4-methoxybenzylthiol (128.0 mg, 0.829 mmol). The crude was purified by column chromatography (hexane/EtOAc, 5/1) to afford **1k** (76.3 mg, 55% yield) as a white solid. m.p. 93-94 °C ; ¹H NMR (400 MHz, CDCl₃) δ ; 7.86 (d, *J* = 8.3 Hz, 2H), 7.44 (d, *J* = 8.4 Hz, 2H), 7.35 (d, *J* = 8.1 Hz, 2H), 7.21 (d, *J* = 8.3 Hz, 2H), 7.00 (d, *J* = 8.6 Hz, 2H), 6.72 (d, *J* = 8.7 Hz, 2H), 4.39 (s, 2H), 3.96 (s, 2H), 3.75 (s, 3H), 2.45 (s, 3H) ; ¹³C NMR (100 MHz, CDCl₃) δ 187.6 (C), 159.1 (C), 143.8 (C), 138.5 (C), 133.0 (C), 132.0 (CH×2), 131.9 (CH×2), 130.4 (CH×2), 129.6 (CH×2), 127.2 (CH×2), 126.9 (C), 122.0 (C), 114.1 (CH×2), 55.4 (CH₃), 43.6 (CH₂), 36.1 (CH₂), 21.8 (CH₃) ; IR (ATR) ν 2927, 2837, 1566, 1509, 1315, 1242, 1154, 1087, 1035, 1012 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₂₂BrNO₃S₂: 503.0224, found: 503.0230

4-Methoxybenzyl (*E*)-2-(pyridin-3-yl)-*N*-tosylethanimidothioate (1l)



Following the General Procedure I, using 3-ethynylpyridine (50.0 mg, 0.485 mmol), tosyl azide (115.0 mg, 0.582 mmol) and 4-methoxybenzylthiol (224.0 mg, 1.455 mmol). The crude was purified by column chromatography (hexane/EtOAc, 1/1) to afford **1l** (140.5 mg, 68% yield) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, *J* = 1.8 Hz, 1H), 8.55-8.53 (m, 1H), 7.84 (d, *J* = 8.3 Hz, 2H), 7.69 (d, *J* = 7.9 Hz, 1H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.27-7.24 (m, 1H), 7.00 (d, *J* = 8.7 Hz), 6.71 (d, *J* = 8.7 Hz, 2H), 4.44 (s, 2H), 3.97 (s, 2H), 3.75 (s, 3H), 2.46 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 186.8 (C), 159.2 (C), 151.1 (CH), 149.1 (CH), 143.9 (C), 138.4 (C), 137.7 (CH), 130.4 (CH×2), 130.0 (C), 129.7 (CH×2), 127.2 (CH×2), 126.8 (C), 123.6 (CH), 114.1 (CH×2), 55.4 (CH₃), 41.5 (CH₂), 36.2 (CH₂), 21.8 (CH₃); IR (ATR) ν 3035, 2925, 2838, 1715, 1551, 1511, 1426, 1302, 1248, 1153, 1087, 1030; HRMS (EI) m/z: [M+H]⁺ calcd. for C₂₂H₂₂N₂O₃S₂: 426.1072, found: 426.1078

4-Methyl-*N*-(4-phenyl-1-(1-phenylvinyl)-1*H*-1,2,3-triazol-5-yl)benzenesulfonamide (3aa)




Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-phenyl-*N*-tosylethanimidothioate **1a** (50.0 mg, 0.117 mmol), tripotassium phosphate (51.0 mg, 0.235 mmol) and (1-azidovinyl)benzene **2a** (51.2 mg, 0.352 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3aa** (41.4 mg, 85%

yield) as a white solid. m.p. 188-190 °C ; ^1H NMR (400 MHz, d₆-DMSO) δ 10.68 (br, 1H), 7.58 (d, *J* = 7.2 Hz, 2H), 7.44-7.39 (m, 3H), 7.33 (d, *J* = 8.1 Hz, 2H), 7.27-7.16 (m, 5H), 6.98 (d, *J* = 8.0 Hz, 2H), 6.15 (s, 1H), 5.61 (s, 1H), 2.19 (s, 3H) ; ^{13}C NMR (100 MHz, d₆-DMSO) δ 143.4, 141.5, 140.1, 137.2, 134.7, 129.3 (CH×2), 129.3, 129.1, 128.6 (CH×2), 128.2 (CH×2), 128.1, 127.8, 126.4 (CH×2), 126.1 (CH×2), 125.9 (CH×2), 115.5, 20.9 ; IR (ATR) ν 3257, 3032, 2922, 2827, 2773, 1596, 1495, 1447, 1407, 1372, 1341, 1240, 1164, 1092 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₂₀N₄O₂S: 416.1307, found: 416.1300.

Gram scale synthetic method of product 3aa: To a solution of thioimide **1a** (1.0 g, 2.35 mmol, 1 equiv) and potassium phosphate (998.0 mg, 4.7 mmol, 2 equiv) in DMSO (7.83 mL) was added vinyl azide **2a** (1.02 g, 7.05 mmol, 3 equiv), the resulting reaction mixture was stirred at 80 °C under nitrogen atmosphere for several hours until the reaction was completed as indicated by TLC. The mixture was extracted with DCM for three times and the combined organic phase was washed with 2N HCl solution and brine, dried over MgSO₄, filtered and concentrated. The crude product was purified by flash column chromatography to afford the desired products **3aa** (684.5 mg, 70%) as a white solid.


***N*-(4-(4-Methoxyphenyl)-1-(1-phenylvinyl)-1*H*-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (**3ba**)**



Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-(4-methoxyphenyl)-*N*-tosylethanimidothioate **1b** (50.0 mg, 0.110 mmol), tripotassium phosphate (46.7 mg,

0.22 mmol) and (1-azidovinyl)benzene **2a** (47.8 mg, 0.329 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ba** (34.4 mg, 70% yield) as a white solid. m.p. 199-200 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 10.59 (br, 1H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.43-7.38 (m, 3H), 7.33 (d, *J* = 8.2 Hz, 2H), 7.20-7.18 (m, 2H), 7.01 (d, *J* = 8.2 Hz, 2H), 6.76 (d, *J* = 8.8 Hz, 2H), 6.13 (s, 1H), 5.59 (s, 1H), 3.77 (s, 3H), 2.20 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 159.1, 143.3, 141.5, 140.1, 137.4, 134.8, 129.3 (CH×3), 128.6 (CH×2), 127.6 (CH×2), 127.3, 126.4 (CH×2), 125.9 (CH×2), 121.6, 115.3, 113.7 (CH×2), 55.1, 20.8 ; IR (ATR) ν 3000, 2837, 2762, 1620, 1514, 1446, 1375, 1341, 1305, 1251, 1162, 1090 ; HRMS (EI) m/z : [M+H]⁺ calcd. for : C₂₄H₂₂N₄O₃S: 446.1413, found: 446.1411.


4-Methyl-N-(1-(1-phenylvinyl)-4-(*p*-tolyl)-1*H*-1,2,3-triazol-5-yl)benzenesulfonamide (3ca)



Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-(*p*-tolyl)-*N*-tosylethanimidothioate **1c** (50.0 mg, 0.114 mmol), tripotassium phosphate (48.4 mg, 0.228 mmol) and (1-azidovinyl)benzene **2a** (49.8 mg, 0.343 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ca** (39.3 mg, 80% yield) as a yellow solid. m.p. 173-174 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 10.59 (br, 1H), 7.41 (d, *J* = 7.0 Hz, 2H), 7.39-7.34 (m, 3H), 7.28 (d, *J* = 7.0 Hz, 2H), 7.17-7.174(m, 2H), 6.96 (t, *J* = 8.8 Hz, 4H), 6.10 (s, 1H), 5.55 (s, 1H), 2.25 (s, 3H), 2.17 (s, 3H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 143.4, 141.6, 140.1, 137.4, 137.3, 134.8, 129.3 (CH×3), 128.8 (CH×2), 128.6 (CH×2), 127.8, 126.4 (CH×2), 126.3, 126.1 (CH×2), 125.9 (CH×2), 115.4, 20.9, 20.9 ; IR (ATR) ν 3261, 3035, 2922, 2831, 2777, 1595, 1514, 1376,


1341, 1238, 1159, 1089 ; HRMS (EI) m/z : [M+H]⁺ calcd. for: C₂₄H₂₂N₄O₂S: 430.1463, found: 430.1461.

N-(4-(3-Methoxyphenyl)-1-(1-phenylvinyl)-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3da)




Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-(3-methoxyphenyl)-*N*-tosylethanimidothioate **1d** (50.0 mg, 0.110 mmol), tripotassium phosphate (46.7 mg, 0.22 mmol) and (1-azidovinyl)benzene **2a** (47.8 mg, 0.329 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3da** (37.3 mg, 76% yield) as a yellow solid. m.p. 67-69 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.32 (m, 5H), 7.19-7.11 (m, 4H), 7.08 (t, *J* = 8.1 Hz, 1H), 6.96 (d, *J* = 8.0 Hz, 2H), 6.78 (dd, *J* = 8.1, 1.5 Hz, 1H), 6.59 (br, 1H), 5.72 (s, 1H), 5.59 (s, 1H), 3.75 (s, 3H), 2.29 (s, 3H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 159.0, 143.3, 141.5, 140.1, 137.1, 134.8, 130.4, 129.3 (CH×4), 128.6 (CH×2), 128.2, 126.4 (CH×2), 125.9 (CH×2), 118.7, 115.6, 113.9, 111.2, 55.1, 20.9 ; IR (ATR) ν 3244, 3063, 3000, 2959, 2927, 2836, 1585, 1495, 1447, 1370, 1335, 1292, 1243, 1162, 1091, 1050 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₄H₂₂N₄O₃S: 446.1413, found: 446.1411.

4-Methyl-N-(4-(naphthalen-2-yl)-1-(1-phenylvinyl)-1H-1,2,3-triazol-5-yl)benzenesulfonamide (3ea)



Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-(naphthalen-2-yl)-*N*-tosylethanimidothioate **1e** (50.0 mg, 0.105 mmol), tripotassium phosphate (44.6 mg, 0.21 mmol) and (1-azidovinyl)benzene **2a** (45.8 mg, 0.315 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ea** (37.2 mg, 76% yield) as a white solid. m.p. 204-205 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 7.98 (s, 1H), 7.86-7.81 (m, 1H), 7.73-7.64 (m, 3H), 7.48-7.46 (m, 2H), 7.40-7.38 (m, 3H), 7.27 (d, *J* = 8.2 Hz, 2H), 7.23-7.21 (m, 2H), 6.66 (d, *J* = 8.2 Hz, 2H), 6.17 (s, 1H), 5.64 (s, 1H), 1.72 (s, 3H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 143.2, 141.3, 140.2, 137.4, 134.9, 132.6, 132.4, 129.3, 129.1 (CH×2), 128.7, 128.6 (CH×2), 128.1, 127.7, 127.5, 126.6, 126.3 (CH×3), 126.2, 126.0 (CH×2), 125.2, 124.0, 115.5, 20.5 ; IR (ATR) ν 3000, 2926, 2824, 2755, 1580, 1421, 1345, 1248, 1163, 1092, 1019 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₇H₂₂N₄O₂S: 466.1463, found: 466.1471.

N-(4-(tert-Butyl)-1-(1-phenylvinyl)-1*H*-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3fa)




3fa

Following the General Procedure II, using 4-methylbenzyl (*E*)-3,3-dimethyl-*N*-tosylbutanimidothioate **1f** (50.0 mg, 0.128 mmol), tripotassium phosphate (54.3 mg, 0.256 mmol) and (1-azidovinyl)benzene **2a** (55.9 mg, 0.385 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3fa** (34.0 mg, 67% yield) as a white solid. m.p. 77-79 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 10.13 (s, 1H), 7.42 (d, *J* = 8.1 Hz, 2H), 7.32-7.25 (m, 3H), 7.11 (d, *J* = 8.0 Hz, 2H), 6.90 (d, *J* = 7.3


Hz, 2H), 5.74 (s, 1H), 5.29 (s, 1H), 2.24 (s, 3H), 1.26 (s, 9H) ; ^{13}C NMR (100 MHz, d₆-DMSO) δ 150.5, 143.2, 140.0, 138.1, 134.5, 129.3 (CH×2), 129.1, 128.2 (CH×2), 126.8, 126.6 (CH×2), 125.7 (CH×2), 114.6, 31.4, 39.8, 21.0 ; IR (ATR) ν 3247, 3065, 2960, 2871, 1567, 1447, 1394, 1337, 1271, 1157, 1091, 1021 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₁H₂₄N₄O₂S: 396.1620, found: 396.1617.

4-Methyl-N-(4-(4-nitrophenyl)-1-(1-phenylvinyl)-1H-1,2,3-triazol-5-yl)benzenesulfonamide (3ga)




Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-(4-nitrophenyl)-*N*-tosylethanimidothioate **1g** (50.0 mg, 0.106 mmol), tripotassium phosphate (45.0 mg, 0.212 mmol) and (1-azidovinyl)benzene **2a** (46.3 mg, 0.319 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ga** (27.4 mg, 56% yield) as a white solid. m.p. 205-206 °C ; ^1H NMR (400 MHz, d₆-DMSO) δ 10.91 (br, 1H), 8.04 (d, *J* = 8.7 Hz, 2H), 7.77 (d, *J* = 8.8 Hz, 2H), 7.43-7.42 (m, 3H), 7.33 (d, *J* = 8.1 Hz, 2H), 7.24-7.22 (m, 2H), 6.98 (d, *J* = 8.1 Hz, 2H), 6.24 (s, 1H), 5.67 (s, 1H), 2.10 (s, 3H) ; ^{13}C NMR (100 MHz, d₆-DMSO) δ 146.4, 143.7, 139.9, 139.5, 137.1, 135.7, 134.6, 129.8, 129.4 (CH×2), 128.7 (CH×2), 127.1 (CH×2), 126.6 (CH×2), 126.0 (CH×2), 123.5 (CH×2), 116.0, 20.6 ; IR (ATR) ν 3000, 2937, 2829, 2755, 1601, 1574, 1516, 1420, 1344, 1263, 1239, 1166, 1094 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₁₉N₅O₄S: 461.1158, found: 461.1161.

N-(4-(4-Chlorophenyl)-1-(1-phenylvinyl)-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3ha)



Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-(4-chlorophenyl)-*N*-tosylethanimidothioate **1h** (50.0 mg, 0.109 mmol), tripotassium phosphate (46.3 mg, 0.218 mmol) and (1-azidovinyl)benzene **2a** (47.5 mg, 0.326 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ha** (31.9 mg, 65% yield) as a yellow solid. m.p. 189–191 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 10.73 (br, 1H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.43 – 7.41 (m, 3H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.26 – 7.21 (m, 4H), 7.01 (d, *J* = 7.9 Hz, 2H), 6.20 (s, 1H), 5.63 (s, 1H), 2.24 (s, 3H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 143.7, 140.5, 140.0, 137.3, 134.7, 132.7, 129.3 (CH×3), 128.6 (CH×2), 128.5, 128.3 (CH×2), 128.0, 127.8 (CH×2), 126.5 (CH×2), 125.9 (CH×2), 115.7, 21.0 ; IR (ATR) ν 3109, 3067, 2925, 2829, 1633, 1597, 1494, 1367, 1336, 1163, 1087; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₁₉ClN₄O₂S: 450.0917, found: 450.0912.


N-(4-(4-Acetylphenyl)-1-(1-phenylvinyl)-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3ia)



Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-(4-acetylphenyl)-*N*-tosylethanimidothioate **1i** (50.0 mg, 0.107 mmol), tripotassium phosphate (45.4 mg, 0.214 mmol) and (1-azidovinyl)benzene **2a** (46.6 mg, 0.321 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ia** (33.4 mg, 68% yield).


yield) as a white solid. m.p. 193-194 °C ; ^1H NMR (400 MHz, d₆-DMSO) δ 10.82 (br, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.68 (d, J = 8.3 Hz, 2H), 7.43-7.41 (m, 3H), 7.32 (d, J = 8.2 Hz, 2H), 7.23-7.21 (m, 2H), 6.97 (d, J = 8.1 Hz, 2H), 6.20 (s, 1H), 5.64 (s, 1H), 2.59 (s, 3H), 2.10 (s, 3H); ^{13}C NMR (100 MHz, d₆-DMSO) δ 197.4, 143.5, 140.5, 140.0, 137.1, 135.7, 134.7, 133.6, 129.4 (CH×3), 129.1, 128.6 (CH×2), 128.1 (CH×2), 126.5 (CH×2), 126.1 (CH×2), 125.9 (CH×2), 115.8, 26.7, 20.7 ; IR (ATR) ν 3133, 3061, 2964, 2928, 2858, 1674, 1614, 1404, 1361, 1265, 1166, 1094 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₅H₂₂N₄O₃S: 458.1413, found: 458.1418.

N-(4-(2-Bromophenyl)-1-(1-phenylvinyl)-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3ja)




Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-(2-bromophenyl)-N-tosylethanimidothioate **1j** (50.0 mg, 0.099 mmol), tripotassium phosphate (42.0 mg, 0.198 mmol) and (1-azidovinyl)benzene **2a** (43.1 mg, 0.297 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ja** (36.8 mg, 75% yield) as a yellow solid. m.p. 81-83 °C ; ^1H NMR (400 MHz, d₆-DMSO) δ 10.65 (br, 1H), 7.51-7.47 (m, 1H), 7.44-7.41 (m, 3H), 7.29 (d, J = 8.2 Hz, 2H), 7.25-7.19 (m, 5H), 6.97 (d, J = 8.0 Hz, 2H), 6.25 (s, 1H), 5.63 (s, 1H), 2.23 (s, 3H) ; ^{13}C NMR (100 MHz, d₆-DMSO) δ 142.9, 141.5, 139.5, 137.0, 134.8, 132.7, 131.8, 130.1 (CH, C), 129.7, 129.3, 129.2 (CH×2), 128.6 (CH×2), 127.3, 126.0 (CH×2), 125.8 (CH×2), 122.9, 115.7, 21.0 ; IR (ATR) ν 3202, 3078, 2921, 2854, 1667, 1599, 1478, 1446, 1365, 1338, 1158, 1091, 1046, 1028 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₁₉BrN₄O₂S: 494.0412, found: 494.0406.

N-(4-(4-Bromophenyl)-1-(1-phenylvinyl)-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3ka)



Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-(4-bromophenyl)-*N*-tosylethanimidothioate **1k** (50.0 mg, 0.099 mmol), tripotassium phosphate (42.0 mg, 0.198 mmol) and (1-azidovinyl)benzene **2a** (43.1 mg, 0.297 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ka** (34.3 mg, 70% yield) as a yellow solid. m.p. 200-201 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 10.73 (br, 1H), 7.47-7.41 (m, 5H), 7.38 (d, *J* = 8.4 Hz, 2H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.22 (m, 2H), 7.01 (d, *J* = 8.0 Hz, 2H), 6.20 (s, 1H), 5.63 (s, 1H), 2.25 (s, 3H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 143.7, 140.5, 140.0, 137.2, 134.7, 131.2 (CH×2), 129.3 (CH×3), 128.6 (CH×2), 128.5, 128.4, 128.1 (CH×2), 126.5 (CH×2), 126.0 (CH×2), 121.3, 115.7, 21.1 ; IR (ATR) ν 3108, 3057, 2923, 2851, 1598, 1489, 1398, 1367, 1335, 1258 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₁₉BrN₄O₂S: 494.0412, found: 494.0403.


4-Methyl-N-(1-(1-phenylvinyl)-4-(pyridin-3-yl)-1H-1,2,3-triazol-5-yl)benzenesulfonamide (3la)



Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-(pyridin-3-yl)-*N*-tosylethanimidothioate **1i** (50.0 mg, 0.117 mmol), tripotassium phosphate (49.7 mg, 0.234 mmol) and (1-azidovinyl)benzene **2a** (51.1 mg, 0.352 mmol). The crude was


purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ia** (29.3 mg, 60% yield) as a yellow solid. m.p. 183-185 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 8.77 (s, 1H), 8.44 (s, 1H), 7.86 (d, *J* = 7.2 Hz, 1H), 7.42 (s, 3H), 7.33 (d, *J* = 7.6 Hz, 2H), 7.22 (s, 3H), 6.97 (d, *J* = 7.6 Hz, 2H), 6.18 (s, 1H), 5.63 (s, 1H), 2.18 (s, 3H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 148.5, 146.9, 143.5, 140.0, 139.0, 136.9, 134.7, 133.3, 129.4 (CH×2), 129.3, 129.2, 128.6 (CH×2), 126.5 (CH×2), 125.9 (CH×2), 125.3, 123.2, 115.7, 20.9 ; IR (ATR) ν 3061, 2925, 2853, 1709, 1599, 1447, 1342, 1259, 1164, 1091 ; HRMS (ESI) m/z : [M+H]⁺ calcd. for C₂₂H₁₉N₅O₂S: 417.1259, found: 417.1253.

N-(1-(4-Chlorophenyl)vinyl)-4-phenyl-1*H*-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3ab)




Following the General Procedure II, using 4-methoxybenzyl (*E*)-2-phenyl-*N*-tosylethanimidothioate **1a** (50.0 mg, 0.117 mmol), tripotassium phosphate (49.7 mg, 0.234 mmol) and 1-(1-azidovinyl)-4-chlorobenzene **2b** (63.2 mg, 0.352 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ab** (38.0 mg, 72% yield) as a white solid. m.p. 189-190 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 10.69 (br, 1H), 7.58 (d, *J* = 8.3 Hz, 2H), 7.47 (d, *J* = 8.7 Hz, 2H), 7.32 (d, *J* = 8.3 Hz, 2H), 7.26 -7.17 (m, 5H), 6.97 (d, *J* = 8.0 Hz, 2H), 6.17 (d, *J* = 1.7 Hz, 1H), 5.63 (d, *J* = 1.7 Hz, 1H), 2.19 (s, 3H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 143.5, 141.6, 139.0, 137.0, 134.0, 133.5, 129.4 (CH×2), 129.0, 128.6 (CH×2), 128.3 (CH×2), 128.0, 127.9, 127.8 (CH×2), 126.5 (CH×2), 126.1 (CH×2), 116.1, 20.9 ; IR (ATR) ν 3229, 3070, 2918, 1598, 1492, 1398, 1369, 1170, 1088, 1014 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₁₉ClN₄O₂S: 450.0917, found: 450.0927.

4-Methyl-N-(4-phenyl-1-(*p*-tolyl)vinyl)-1*H*-1,2,3-triazol-5-yl)benzenesulfonamide (3ac)



Following the General Procedure II, using **1a** (50.0 mg, 0.117 mmol), tripotassium phosphate (49.7 mg, 0.234 mmol) and 1-(1-azidovinyl)-4-methylbenzene **2c** (56.0 mg, 0.352 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ac** (40.3 mg, 80% yield) as a white solid. m.p. 139–141 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 10.64 (br, 1H), 7.57 (d, *J* = 7.3 Hz, 2H), 7.31 (d, *J* = 8.1 Hz, 2H), 7.26 – 7.18 (m, 5H), 7.05 (d, *J* = 8.0 Hz, 2H), 6.97 (d, *J* = 8.1 Hz, 2H), 6.08 (s, 1H), 5.52 (s, 1H), 2.34 (s, 3H), 2.19 (s, 3H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 143.3, 141.4, 140.0, 138.9, 137.2, 132.0, 129.3, (CH×2) 129.2, 129.1 (CH×2), 128.2 (CH×2), 128.1, 127.7, 126.4 (CH×2), 126.1 (CH×2), 125.8 (CH×2), 114.5, 20.9, 20.8 ; IR (ATR) ν 3269, 3032, 2922, 2824, 2742, 1598, 1495, 1342, 1240, 1165, 1092 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₄H₂₂N₄O₂S: 430.1463, found: 430.1458.


4-Methyl-N-(1-(1-(naphthalen-2-yl)vinyl)-4-phenyl-1*H*-1,2,3-triazol-5-yl)benzenesulfonamide (3ad)



Following the General Procedure II, using **1a** (50.0 mg, 0.117 mmol), tripotassium phosphate (49.7 mg, 0.234 mmol) and 2-(1-azidovinyl)naphthalene **2d** (68.7 mg, 0.352

mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ad** (49.1 mg, 90% yield) as an orange solid. m.p. 188-189 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 10.68 (br, 1H), 7.94 (d, *J* = 8.4 Hz, 2H), 7.92 - 7.87 (m, 1H), 7.69-7.65 (m, 2H), 7.58 - 7.51 (m, 3H), 7.45 (dd, *J* = 8.7, 1.9 Hz, 1H), 7.34 (d, *J* = 8.3 Hz, 2H), 7.30 -7.22 (m, 3H), 6.92 (d, *J* = 8.0 Hz, 2H), 6.29 (d, *J* = 1.5 Hz, 1H), 5.71 (d, *J* = 1.5 Hz, 1H), 2.10 (s, 3H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 143.4, 141.6, 140.1 137.1, 133.1, 132.5, 132.0, 129.3, 129.7, 128.6, 128.3, 128.2, 128.1, 127.8, 127.5, 127.0, 126.7, 126.5, 126.2, 125.3, 123.4, 116.2, 20.8 ; IR (ATR) ν 3059, 2922, 1636, 1598, 1495, 1402, 1340, 1250, 1162, 1092 ; HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₇H₂₂N₄O₂S: 466.1463, found: 466.1467.


***N*-(1-(1-(4-Methoxyphenyl)vinyl)-4-phenyl-1*H*-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3ae)**



Following the General Procedure II, using **1a** (50.0 mg, 0.117 mmol), tripotassium phosphate (49.7 mg, 0.234 mmol) and 1-(1-azidovinyl)-4-methoxybenzene **2e** (61.7 mg, 0.352 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ae** (26.1 mg, 50% yield) as a yellow solid. m.p. 149-151 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.64 (dd, *J* = 7.9, 1.4 Hz, 2H), 7.34 (d, *J* = 8.3 Hz, 2H), 7.27 - 7.15 (m, 3H), 7.04 (d, *J* = 8.7 Hz, 2H), 6.96 (d, *J* = 8.3 Hz, 2H), 6.85 (d, *J* = 8.8 Hz, 2H), 5.55 (d, *J* = 1.0 Hz, 1H), 5.40 (d, *J* = 1.0 Hz, 1H), 3.80 (s, 3H), 2.28 (s, 3H) ; ¹³C NMR (100 MHz, CDCl₃) δ 160.9, 144.6, 143.0, 140.4, 136.0, 129.6 (CH×2), 129.1, 128.4 (CH×2),


128.3, 127.6 (CH \times 2), 127.5 (CH \times 2), 127.0, 126.8 (CH \times 2, C), 114.5 (CH \times 2), 113.0, 55.5, 21.6 ; IR (ATR) ν 3067, 3000, 2934, 2833, 1642, 1606, 1512, 1424, 1341, 1250, 1164, 1091, 1030 ; HRMS (EI) m/z : [M+H] $^{+}$ calcd. for C₂₄H₂₂N₄O₃S: 446.1413, found: 446.1421.

N-(1-(1-Mesitylvinyl)-4-phenyl-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3af)




Following the General Procedure II, using **1a** (50.0 mg, 0.117 mmol), tripotassium phosphate (49.7 mg, 0.234 mmol) and 2-(1-azidovinyl)-1,3,5-trimethylbenzene **2f** (65.9 mg, 0.352 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3af** (39.7 mg, 74% yield) as a white solid. m.p. 227-228 °C. ¹H NMR (400 MHz, d₆-DMSO) δ 10.48 (br, 1H), 7.34 (d, *J* = 7.5 Hz, 2H), 7.26 (d, *J* = 8.1 Hz, 2H), 7.15 (t, *J* = 7.3 Hz, 1H), 7.04 (t, *J* = 7.6 Hz, 2H), 6.94 - 6.87 (m, 4H), 6.33 (s, 1H), 5.44 (s, 1H), 2.26 (s, 3H), 2.16 (s, 3H), 2.13 (s, 6H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 143.4, 142.2, 139.2, 137.7, 137.2, 136.7, 132.1, 129.3 (CH \times 2), 129.0, 128.6 (CH \times 2), 128.0 (CH \times 2), 127.3, 127.1, 126.5 (CH \times 2), 126.4 (CH \times 2), 114.6, 20.9, 20.7, 19.8 (CH₃ \times 2) ; IR (ATR) ν 3133, 2998, 2966, 2922, 2857, 2814, 2739, 1648, 1495, 1427, 1266, 1166, 1092, 1054. HRMS (EI) m/z : [M+H] $^{+}$ calcd. for C₂₆H₂₆N₄O₂S: 458.1776, found: 458.1773.

4-Methyl-N-(1-(oct-1-en-2-yl)-4-phenyl-1H-1,2,3-triazol-5-yl)benzenesulfonamide (3ag)



Following the General Procedure II, using **1a** (50.0 mg, 0.117 mmol), tripotassium phosphate (49.7 mg, 0.234 mmol) and 2-azidoct-1-ene **2g** (53.9 mg, 0.352 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ag** (27.3 mg, 55% yield) as a white solid. m.p. 137-138 °C ; ¹H NMR (400 MHz, CDCl₃) δ 7.38 - 7.28 (m, 4H), 7.16 (t, *J* = 7.3 Hz, 1H), 7.08 (t, *J* = 7.4 Hz, 2H), 6.88 (d, *J* = 8.0 Hz, 2H), 5.34 (s, 1H), 5.26 (s, 1H), 2.59 (t, *J* = 7.6 Hz, 2H), 2.26 (s, 3H), 1.53 – 1.48 (m, 2H), 1.41-1.23 (m, 6H), 0.89 (t, *J* = 6.8 Hz, 3H) ; ¹³C NMR (100 MHz, CDCl₃) δ 144.5, 143.1, 142.7, 135.8, 129.5 (CH×2), 129.1, 128.4 (CH×2), 128.0, 127.4 (CH×2), 126.9 (CH×2), 126.1, 112.1, 34.5, 31.7, 28.8, 26.6, 22.7, 21.6, 14.2 ; IR (ATR) ν 3060, 2961, 2921, 2854, 1670, 1596, 1493, 1434, 1342, 1291, 1165, 1088 ; HRMS (EI) m/z: [M+H]⁺ calcd. for C₂₃H₂₈N₄O₂S: 424.1933, found: 424.1938.


***N*-(1-(1-Cyclohexylvinyl)-4-phenyl-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3ah)**



Following the General Procedure II, using **1a** (50.0 mg, 0.117 mmol), tripotassium phosphate (49.7 mg, 0.234 mmol) and (1-azidovinyl)cyclohexane **2h** (53.2 mg, 0.352 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to


afford **3ah** (19.8 mg, 40% yield) as a white solid. m.p. 199–200 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 10.60 (br, 1H), 7.52 (d, *J* = 6.9 Hz, 2H), 7.36 (d, *J* = 8.2 Hz, 2H), 7.24–7.15 (m, 3H), 7.06 (d, *J* = 8.2 Hz, 2H), 5.33 (s, 1H), 5.26 (s, 1H), 2.53 – 2.46 (m, 1H), 2.23 (s, 3H), 1.69 – 1.54 (m, 5H), 1.24 – 0.99 (m, 6H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 146.5, 143.4, 141.8, 137.5, 129.4 (CH×2), 129.3, 128.2 (CH×2), 127.7, 127.0, 126.5 (CH×2), 126.2 (CH×2), 111.8 (CH₂), 41.2, 30.4, 25.7, 20.9. IR (ATR) ν 3059, 2924, 2854, 1656, 1496, 1451, 1423, 1346, 1165, 1091. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₂₆N₄O₂S: 422.1776, found: 422.1767.

4-Methyl-N-(4-phenyl-1-(1-(thiophen-2-yl)vinyl)-1*H*-1,2,3-triazol-5-yl)benzenesulfonamide (3ai)




Following the General Procedure II, using **1a** (50.0 mg, 0.117 mmol), tripotassium phosphate (49.7 mg, 0.234 mmol) and 2-(1-azidovinyl)thiophene **2i** (53.2 mg, 0.352 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3ai** (26.2 mg, 53% yield) as a brown solid. m.p. 165–167 °C ; ¹H NMR (400 MHz, d₆-DMSO) δ 10.74 (br, 1H), 7.63 – 7.60 (m, 3H), 7.33 (d, *J* = 8.2 Hz, 2H), 7.28 – 7.20 (m, 3H), 7.06 (dd, *J* = 5.0, 3.8 Hz, 1H), 6.99 (d, *J* = 8.1 Hz, 2H), 6.89 – 6.84 (m, 1H), 5.96 (s, 1H), 5.45 (s, 1H), 2.21 (s, 3H) ; ¹³C NMR (100 MHz, d₆-DMSO) δ 143.4, 141.4, 138.1, 137.1, 134.7, 129.3 (CH×2), 129.1, 128.3 (CH×2), 127.9, 127.8 (CH, C), 127.7, 126.8, 126.4 (CH×2), 126.2 (CH×2), 113.9, 20.9. IR (ATR) ν 3112, 3039, 2922, 2850, 1630, 1498, 1435, 1372, 1337, 1234, 1163, 1090. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₁H₁₈N₄O₂S₂: 422.0817, found: 422.0868.

N-(1-(4-Chlorophenyl)vinyl)-4-(*p*-tolyl)-1*H*-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3cb**)**



Following the General Procedure II, using 4-methoxybenzyl (*Z*)-2-(*p*-tolyl)-*N*-tosylethanimidothioate **1c** (50.0 mg, 0.114 mmol), tripotassium phosphate (48.4 mg, 0.228 mmol) and 1-(1-azidovinyl)-4-chlorobenzene **2b** (61.2 mg, 0.341 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3cb** (43.5 mg, 82% yield) as a white solid. m.p. 202–203 °C. ¹H NMR (400 MHz, d₆-DMSO) δ 10.64 (br, 1H), 7.48 – 7.44 (m, 4H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.20 (d, *J* = 8.5 Hz, 2H), 7.02 (d, *J* = 8.0 Hz, 2H), 6.99 (d, *J* = 8.1 Hz, 2H), 6.17 (s, 1H), 5.62 (s, 1H), 2.29 (s, 3H), 2.21 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 143.4, 141.6, 139.0, 137.4, 137.3, 133.9, 133.6, 129.2 (CH×2), 128.8 (CH×2), 128.6 (CH×2), 127.8 (CH×2, C), 126.4 (CH×2), 126.3, 126.1 (CH×2), 116.0, 20.9, 20.9. IR (ATR) ν 3239, 3129, 2945, 1651, 1585, 1489, 1398, 1367, 1333, 1238, 1164, 1093. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₄H₂₁ClN₄O₂S: 464.1074, found: 464.1080.


4-Methyl-N-(4-(*p*-tolyl)-1-(1-(*p*-tolyl)vinyl)-1*H*-1,2,3-triazol-5-yl)benzenesulfonamide (3cc**)**



Following the General Procedure II, using **1c** (50.0 mg, 0.114 mmol), tripotassium phosphate (48.4 mg, 0.228 mmol) and 1-(1-azidovinyl)-4-methylbenzene **2c** (54.3 mg,


0.341 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3cc** (35.5 mg, 70% yield) as an orange solid. m.p. 186-187 °C. ¹H NMR (400 MHz, d₆-DMSO) δ 10.59 (br, 1H), 7.45 (d, *J* = 8.1 Hz, 2H), 7.31 (d, *J* = 8.2 Hz, 2H), 7.21 (d, *J* = 8.1 Hz, 2H), 7.07 (d, *J* = 8.2 Hz, 2H), 7.01 - 6.96 (m, 4H), 6.07 (s, 1H), 5.52 (s, 1H), 2.34 (s, 3H), 2.29 (s, 3H), 2.21 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 143.4, 141.6, 140.1, 138.9, 137.4, 137.3, 132.0, 129.2 (CH×2), 129.1 (CH×2), 128.8 (CH×2), 127.7, 126.4 (CH×2), 126.4, 126.1 (CH×2), 125.8 (CH×2), 114.4, 20.9, 20.9, 20.8. IR (ATR) ν 3000, 2922, 2826, 2758, 1641, 1586, 1511, 1448, 1343, 1256, 1163, 1091. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₅H₂₄N₄O₂S: 444.1620, found: 444.1629.

***N*-(4-(4-Chlorophenyl)-1-(4-chlorophenyl)vinyl)-1*H*-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (**3hb**)**




Following the General Procedure II, using **1h** (50.0 mg, 0.109 mmol), tripotassium phosphate (46.3 mg, 0.218 mmol) and 1-(1-azidovinyl)-4-chlorobenzene **2b** (58.6 mg, 0.326 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3hb** (31.7 mg, 60% yield) as a white solid. m.p. 206-207 °C. ¹H NMR (400 MHz, d₆-DMSO) δ 10.75 (br, 1H), 7.53 (d, *J* = 8.4 Hz, 2H), 7.48 (d, *J* = 8.5 Hz, 2H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.25 (d, *J* = 8.7 Hz, 2H), 7.23 (d, *J* = 8.7 Hz, 2H), 7.00 (d, *J* = 8.0 Hz, 2H), 6.23 (s, 1H), 5.67 (s, 1H), 2.23 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 143.7, 140.5, 138.9, 137.1, 134.0, 133.5, 132.8, 129.3 (CH×2), 128.6 (CH×2), 128.4, 128.3 (CH×2), 127.9, 127.8 (CH×4), 126.5 (CH×2), 116.3, 21.0. IR (ATR) ν 3053, 3972, 2923, 2826, 2751, 1644, 1596, 1489, 1367, 1165, 1086. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₁₈Cl₂N₄O₂S: 484.0528, found: 484.0520.

N-(4-(4-Chlorophenyl)-1-(*p*-tolyl)vinyl)-1*H*-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (3hc)



Following the General Procedure II, using 4-methoxybenzyl (*Z*)-2-(4-chlorophenyl)-*N*-tosylethanimidothioate **1h** (50.0 mg, 0.109 mmol), tripotassium phosphate (46.3 mg, 0.218 mmol) and 1-(1-azidovinyl)-4-methylbenzene **2c** (51.9 mg, 0.326 mmol). The crude was purified by column chromatography (hexane/EtOAc, 3:1) to afford **3hc** (32.4 mg, 64% yield) as a yellow solid. m.p. 191-192 °C. ¹H NMR (400 MHz, d₆-DMSO) δ 10.68 (br, 1H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.31 (d, *J* = 8.0 Hz, 2H), 7.24 - 7.21 (m, 4H), 7.09 (d, *J* = 8.0 Hz, 2H), 7.00 (d, *J* = 8.3 Hz, 2H), 6.12 (s, 1H), 5.56 (s, 1H), 2.34 (s, 3H), 2.24 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 144.7, 140.5, 140.0, 139.0, 137.3, 132.7, 132.0, 129.3 (CH×2), 129.2 (CH×2), 128.4, 128.3 (CH×2), 128.0, 127.8 (CH×2), 126.5 (CH×2), 125.8 (CH×2), 114.7, 21.0, 20.8. IR (ATR) ν 3031, 2920, 2836, 2782, 1641, 1610, 1493, 1340, 1250, 1163, 1090. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₄H₂₁ClN₄O₂S: 464.1074, found: 464.1068.


N-(1,4-Diphenyl-1*H*-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (5aa)



Following the General Procedure III, using *N*-sulfonylthioimidate **1a'** (100.0 mg, 0.253 mmol), tripotassium phosphate (107.4 mg, 0.506 mmol) and azidobenzene **4a** (90.3 mg,


0.758 mmol). The crude was purified by column chromatography (hexane/EtOAc, 4:1) to afford **5aa** (69.2 mg, 70% yield) as a white solid. m.p. 235-236 °C. ¹H NMR (400 MHz, d-acetone) δ 9.28 (br, 1H), 7.79 – 7.76 (m, 2H), 7.62 – 7.56 (m, 2H), 7.55 – 7.51 (m, , 3H), 7.34 – 7.23 (m, 5H), 6.99 (d, *J* = 7.9 Hz, 2H), 2.29 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 143.5, 142.4, 136.9, 135.1, 129.5 (CH×2), 129.4, 129.3, 128.5, 128.1, 127.3, 126.3, 126.3, 124.8, 21.0. IR (ATR) ν 3261, 1699, 1601, 1373, 1336, 1161, 830, 725, 695. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₁H₁₈N₄O₂S: 390.1150, found: 390.1156.

4-Methyl-N-(4-phenyl-1-(p-tolyl)-1H-1,2,3-triazol-5-yl)benzenesulfonamide (5ab)




Following the General Produce III, using benzyl (Z)-2-phenyl-N-tosylethanimidothioate **1a'** (100.0 mg, 0.253 mmol), tripotassium phosphate (107.4 mg, 0.506 mmol) and 1-azido-4-methylbenzene **4b** (100.9 mg, 0.758 mmol) and DMSO (0.843 ml, 0.3M). The crude was purified by column chromatography (hexane/EtOAc, 4:1) to afford **5ab** (75.7 mg, 74% yield) as a white solid. m.p. 212-213 °C. ¹H NMR (400 MHz, d-acetone) δ 9.25 (br, 1H), 7.83 – 7.78 (m, 2H), 7.43 (d, *J* = 8.3 Hz, 2H), 7.31 – 7.28 (m, 7H), 7.01 (d, *J* = 8.0 Hz, 2H), 2.44 (s, 3H), 2.31 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 144.4, 143.3, 140.4, 137.5, 133.0, 130.5, 130.1, 129.7, 129.3, 129.0, 128.0, 126.9, 126.8, 125.2, 21.6, 21.4. IR (ATR) ν 3049, 1512, 1340, 1165, 1093, 986, 817, 727, 697, 656. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₂H₂₀N₄O₂S: 404.1307, found: 404.1302.

N-(1-(4-Ethylphenyl)-4-phenyl-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (5ac)



Following the General Procedure III, using benzyl (Z)-2-phenyl-N-tosylethanimidothioate **1a'** (100.0 mg, 0.253 mmol), tripotassium phosphate (107.4 mg, 0.506 mmol) and 1-azido-4-ethylbenzene **4c** (111.6 mg, 0.758 mmol). The crude was purified by column chromatography (hexane/EtOAc, 4:1) to afford **5ac** (75.2 mg, 71% yield) as a white solid. m.p. 213–214 °C. ¹H NMR (400 MHz, d₆-DMSO) δ 10.78 (br, 1H), 7.78 – 7.70 (m, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 7.33 – 7.28 (m, 5H), 7.21 (d, *J* = 8.3 Hz, 2H), 6.95 (d, *J* = 8.0 Hz, 2H), 2.69 (q, *J* = 7.6 Hz, 2H), 2.23 (s, 3H), 1.24 (t, *J* = 7.6 Hz, 3H). ; ¹³C NMR (100 MHz, d₆-DMSO) δ 145.2, 143.2, 142.3, 137.0, 132.7, 129.4, 129.3, 128.4, 128.4, 127.9, 127.1, 126.1 (CH×2), 124.6, 27.8, 20.9, 15.3. IR (ATR) ν 3057, 1735, 1596, 1569, 1514, 1341, 1165, 1091, 986, 880, 838, 815, 724, 693, 661. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₂₂N₄O₂S: 418.1463, found: 418.1461.


N-(1-(4-Methoxyphenyl)-4-phenyl-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (5ad)



Following the General Procedure III, benzyl (Z)-2-phenyl-N-tosylethanimidothioate **1a'** (100.0 mg, 0.253 mmol), tripotassium phosphate (107.4 mg, 0.506 mmol) and 1-azido-4-methoxybenzene **4d** (113.1 mg, 0.758 mmol). The crude was purified by column chromatography (hexane/EtOAc, 4:1) to afford **5ad** (70.0 mg, 64% yield) as a white solid. m.p. 188–190 °C. ¹H NMR (400 MHz, d₆-DMSO) δ 10.78 (br, 1H), 7.78 – 7.70 (m, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 7.33 – 7.28 (m, 5H), 7.21 (d, *J* = 8.3 Hz, 2H), 6.95 (d, *J* = 8.0 Hz, 2H), 2.69 (q, *J* = 7.6 Hz, 2H), 2.23 (s, 3H), 1.24 (t, *J* = 7.6 Hz, 3H). ; ¹³C NMR (100 MHz, d₆-DMSO) δ 145.2, 143.2, 142.3, 137.0, 132.7, 129.4, 129.3, 128.4, 128.4, 127.9, 127.1, 126.1 (CH×2), 124.6, 27.8, 20.9, 15.3. IR (ATR) ν 3057, 1735, 1596, 1569, 1514, 1341, 1165, 1091, 986, 880, 838, 815, 724, 693, 661. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₂₂N₄O₃S: 434.1620, found: 434.1618.


chromatography (hexane/EtOAc, 4:1) to afford **5ad** (75.5 mg, 71% yield) as a white solid. m.p. 203-204 °C. ¹H NMR (400 MHz, d-acetone) δ 7.83 – 7.76 (m, 2H), 7.46 (d, *J* = 9.1 Hz, 2H), 7.34 – 7.26 (m, 5H), 7.04 – 6.98 (m, 4H), 3.90 (s, 3H), 2.30 (s, 3H). ; ¹³C NMR (100 MHz, d₆-DMSO) δ 159.8, 143.2, 142.1, 137.2, 129.4, 129.4, 128.4, 127.9, 127.9, 127.3, 126.2, 126.2, 126.1, 114.3, 55.6, 20.9. IR (ATR) ν 3241, 1598, 1515, 1252, 1164, 815, 693, 1489. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₂H₂₀N₄O₃S: 420.1256, found: 420.1253.

***N*-(1-(4-Chlorophenyl)-4-phenyl-1*H*-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (5ae)**




Following the General Procedure III, using benzyl (Z)-2-phenyl-N-tosylethanimidothioate **1a'** (100.0 mg, 0.253 mmol), tripotassium phosphate (107.4 mg, 0.506 mmol) and 1-azido-4-chlorobenzene **4e** (116.4mg, 0.758 mmol). The crude was purified by column chromatography (hexane/EtOAc, 4:1) to afford **5ae** (70.9 mg, 66% yield) as a white solid. m.p. 238-239 °C. ¹H NMR (400 MHz, d-acetone) δ 7.84 – 7.80 (m, 2H), 7.62 – 7.58 (m, 2H), 7.55 – 7.51 (m, 2H), 7.35 – 7.29 (m, 5H), 7.03 (d, *J* = 8.0, 2H), 2.33 (s, 3H). ; ¹³C NMR (100 MHz, d₆-DMSO) δ 143.5, 142.4, 136.9, 134.2, 133.7, 129.4, 129.3, 129.1, 128.4, 128.1, 127.3, 126.3, 126.1 (CH×2), 21.0. IR (ATR) ν 3061, 1743, 1580, 1492, 1405, 1339, 1163, 1091, 985, 832, 724, 695, 655. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₁H₁₇ClN₄O₂S: 424.0761, found: 424.0756.

N-(1-(2-Chlorophenyl)-4-phenyl-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (5af)



Following the General Procedure III, using benzyl (Z)-2-phenyl-N-tosylethanimidothioate **1a'** (100.0 mg, 0.253 mmol), tripotassium phosphate (107.4 mg, 0.506 mmol) and 1-azido-2-chlorobenzene **4f** (116.4 mg, 0.758 mmol). The crude was purified by column chromatography (hexane/EtOAc, 4:1) to afford **5af** (80.6 mg, 75% yield) as a white solid. m.p. 195–196 °C. ¹H NMR (400 MHz, d-acetone) δ ¹H NMR (400 MHz, d-acetone) δ 9.31 (s, 1H), 7.73 (dd, *J* = 7.6, 1.9 Hz, 2H), 7.65 – 7.62 (m, 2H), 7.58 – 7.53 (m, 1H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.30 – 7.24 (m, 3H), 7.03 (d, *J* = 8.3 Hz, 2H), 2.29 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 143.4, 141.1, 136.8, 132.4, 132.0, 130.4, 130.1, 129.4 (CH×2), 129.0, 128.8, 128.3, 127.9, 127.9, 126.2, 126.1, 20.9. IR (ATR) ν 3043, 1589, 1489, 1341, 1159, 1087, 875, 758, 694. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₁H₁₇ClN₄O₂S: 424.0761, found: 424.0764.


N-(1-(4-Iodophenyl)-4-phenyl-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (5ag)



Following the General Procedure III, using benzyl (Z)-2-phenyl-N-tosylethanimidothioate **1a'** (100.0 mg, 0.253 mmol), tripotassium phosphate (107.4 mg, 0.506 mmol) and 1-azido-4-iodobenzene **4g** (185.7 mg, 0.758 mmol). The crude was


purified by column chromatography (hexane/EtOAc, 4:1) to afford **5ag** (111.0 mg, 85% yield) as a white solid. m.p. 238-239 °C. ¹H NMR (400 MHz, d-acetone) δ 7.88 – 7.82 (m, 4H), 7.40 – 7.36 (m, 2H), 7.35 – 7.28 (m, 5H), 7.04 (d, *J* = 7.9 Hz, 2H), 2.36 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 143.5, 142.5, 138.0, 136.9, 134.6, 129.4, 129.2, 128.4, 128.1, 127.1, 126.4, 126.2, 126.1, 96.0, 21.2. IR (ATR) ν 3076, 1743, 1592, 1489, 1403, 1339, 1157, 1088, 984, 884, 821, 723, 690, 653. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₁H₁₇IN₄O₂S: 516.0117, found: 516.0120.

N-(1-(4-Formylphenyl)-4-phenyl-1H-1,2,3-triazol-5-yl)-4-methylbenzenesulfonamide (5ah)




Following the General Procedure III, benzyl (Z)-2-phenyl-N-tosylethanimidothioate **1a'** (100.0 mg, 0.253 mmol), tripotassium phosphate (107.4 mg, 0.506 mmol) and 4-azidobenzaldehyde **4h** (111.5 mg, 0.758 mmol). The crude was purified by column chromatography (hexane/EtOAc, 4:1) to afford **5ah** (85.8 mg, 81% yield) as a white solid. m.p. 219-220 °C. ¹H NMR (400 MHz, d-acetone) δ 10.16 (s, 1H), 8.08 – 8.06 (d, *J* = 8.6 Hz, 2H), 7.86 (d, *J* = 8.4 Hz, 2H), 7.82 – 7.78 (m, 2H), 7.34 – 7.29 (m, 5H), 6.99 (d, *J* = 8.0 Hz, 2H), 2.26 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 192.4, 143.5, 142.7, 139.3, 136.7, 136.2, 130.4, 129.4, 129.0, 128.4, 128.2, 127.3, 126.2, 126.2, 125.0, 20.9. IR (ATR) ν 3083, 3972, 1699, 1602, 1372, 1339, 1161, 1093, 987, 725, 695, 657. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₂H₁₈N₄O₃S: 418.1100, found: 418.1102.

Methyl 4-((4-methylphenyl)sulfonamido)-4-phenyl-1H-1,2,3-triazol-1-yl)benzoate (5ai)



Following the General Procedure III, using benzyl (Z)-2-phenyl-N-tosylethanimidothioate **1a'** (100.0 mg, 0.253 mmol), tripotassium phosphate (107.4 mg, 0.506 mmol) and methyl 4-azidobenzoate **4i** (134.3 mg, 0.758 mmol). The crude was purified by column chromatography (hexane/EtOAc, 4:1) to afford **5ai** (86.2 mg, 76% yield) as a yellow solid. m.p. 238-239 °C. ¹H NMR (400 MHz, d-acetone) δ 9.47 (s, 1H), 8.10 (d, *J* = 8.5 Hz, 2H), 7.84 – 7.81 (m, 2H), 7.75 (d, *J* = 8.5 Hz, 2H), 7.37 – 7.27 (m, 5H), 6.98 (d, *J* = 8.1 Hz, 2H), 3.97 (s, 3H), 2.26 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 165.9, 143.9, 143.1, 138.8, 137.3, 130.6, 130.4, 129.8, 129.3, 128.9, 128.7, 127.9, 126.6, 126.4, 125.0, 53.0, 21.1. IR (ATR) ν 3291, 2919, 2850, 1614, 1531, 1236, 1094, 770, 668. HRMS (EI) m/z : [M+H]⁺ calcd. for C₂₃H₂₀N₄O₄S: 448.1205, found: 448.1201.

4-Methyl-N-(4-phenyl-1-(1-phenylethyl)-1H-1,2,3-triazol-5-yl)benzenesulfonamide (6)




To a solution of the 4-methyl-N-(4-phenyl-1-(1-phenylvinyl)-1H-1,2,3-triazol-5-yl)benzenesulfonamide **3aa** (50 mg, 0.120 mmol, 1.0 equiv) in cosolvent MeOH/EA

(1/2, 0.3M) was added Pd/C catalyst (10%wt, 5.0 mg). The resulting solution was stirred at room temperature under hydrogen balloon for 24 hours. After the reaction was completed, the mixture was filtered by celite and extracted with DCM for three times and the combined organic phase was washed with brine, dried over MgSO₄, filtered and concentrated. The crude was purified by flash column chromatography to afford the desired product **6** (30.2 mg, 60%). ¹H NMR (400 MHz, d₆-DMSO) δ 10.72 (s, 1H), 7.41-7.35 (m, 4H), 7.33 (t, J = 6.8 Hz, 5H), 7.17 (t, J = 7.3 Hz, 1H), 7.10 (t, J = 7.3 Hz, 2H), 6.99 (d, J = 8.1 Hz, 2H), 5.90 (q, J = 7.0 Hz, 1H), 2.18 (s, 3H), 1.91 (d, J = 7.0 Hz, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ 144.2, 141.7, 140.9, 136.7, 130.0 (CH×2), 129.8, 129.2 (CH×2), 128.5 (CH×2, CH), 127.9, 127.2, 127.1 (CH×2), 127.0 (CH×2), 126.5 (CH×2), 56.8, 21.8, 21.4. IR (ATR) ν 3088, 3059, 3034, 2990, 2924, 2812, 2743, 1586, 1495, 1451, 1420, 1339, 1240, 1164, 1090, 1066. HRMS (EI) m/z: [M+H]⁺ calcd. for C₂₃H₂₂N₄O₂S: 418.1463, found: 418.1455.

Methyl (Z)-2-phenyl-N-tosylacetimidate (**7**)⁴

(b)



To a solution of *N*-thioimidate **1a'** (50.0 mg, 0.126 mmol, 1 equiv) in MeOH (0.42 mL, 0.3 M) was added NaN₃ (9.9 mg, 0.152 mmol, 1.2 equiv) and stirred at 50 °C under nitrogen atmosphere. The resulting reaction mixture was reacted for 3 hours until the reaction was complete as indicated by TLC. After the reaction was completed, the mixture was extracted with EtOAc for three times and the combined organic layer was washed with brine, dried over MgSO₄, filtered and concentrated. The crude product was purified by column chromatography (hex/EtOAc = 4/1) to afford **7** (27.8 mg, 73%) as

a white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.84 (d, $J = 8.3$ Hz, 2H), 7.37-7.26 (m, 7H), 4.26 (s, 2H), 3.71 (s, 3H), 2.43 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 173.6, 143.2, 138.9, 133.5, 129.6 (CH \times 2), 129.3 (CH \times 2), 128.6 (CH \times 2), 127.2, 126.7 (CH \times 2), 55.7, 39.5, 21.5.



References:


1. J.-Y. Wu, W.-J. Liao, X.-Y. Lin, C.-F. Liang, *Org. Biomol. Chem.*, 2020, **18**, 8881.
2. (a) R. R. Donthiri, V. Pappula, N. K. Reddy, D. Bairagi, S. Adimurthy, *J. Org. Chem.*, 2014, **79**, 11277; (b) B. Nie, W. Q. Wu, W. Zeng, Q. Ren, J. Zhang, Y. Zhang, H. Jiang, *Adv. Synth. Catal.*, 2020, **362**, 1362.
3. (a) A. C. A. Muraca, C. Raminelli, *ACS Omega*, 2020, **5**, 2240; (b) Y.-S. Li, C.-F. Liang, *J. Chin. Chem. Soc.*, 2022, **69**, 849.
4. E. J. Yoo, I. Bae, S. H. Cho, H. Han, S. Chang, *Org. Lett.*, 2006, **8**, 1347.

Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	CDCl ₃
Temperature	
Experiment	1D
Number of Scans	8
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	3.2980
Acquisition Time	2.4429
Modification Date	2021-05-10T15:39:13
Spectrometer Frequency	399.78
Spectral Width	7204.5
Lowest Frequency	-1198.8
Nucleus	Proton



7.8759
7.8553
7.3490
7.3268
7.3174
7.2595
7.0061
6.9846
6.7165
6.6950


—4.4469
—3.9515
—3.7563
—2.4598






Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	CDCl ₃
Temperature	
Experiment	1D
Number of Scans	8
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	3.2980
Acquisition Time	2.4429
Modification Date	2021-05-10T15:58:09
Spectrometer Frequency	399.78
Spectral Width	7204.5
Lowest Frequency	-1198.8
Nucleus	Proton







Parameter	Value
Origin	Varian
Spectrometer	mercury
Solvent	"cdcl3"
Temperature	25.0
Pulse Sequence	s2pul
Experiment	1D
Number of Scans	16
Receiver Gain	39
Relaxation Delay	1.0000
Pulse Width	0.0000
Acquisition Time	2.5575
Modification Date	2020-07-30T21:40:30
Spectrometer Frequency	400.43
Spectral Width	6406.1
Lowest Frequency	-800.0
Nucleus	1H








Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	"cdcl3"
Temperature	
Experiment	1D
Number of Scans	775
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	4.7316
Acquisition Time	0.6336
Modification Date	2021-05-10T20:49:52
Spectrometer Frequency	100.53
Spectral Width	25252.1
Lowest Frequency	-2573.5
Nucleus	Carbon13




Parameter	Value
Origin	Varian
Spectrometer	vnmr
Solvent	"cdcl3"
Temperature	20.0
Pulse Sequence	s2pul
Experiment	1D
Number of Scans	12
Receiver Gain	48
Relaxation Delay	1.0000
Pulse Width	0.0000
Acquisition Time	2.5559
Modification Date	2021-05-10T22:58:00
Spectrometer Frequency	399.76
Spectral Width	6410.3
Lowest Frequency	-799.6
Nucleus	1H













Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	"cdcl3"
Temperature	
Experiment	1D
Number of Scans	8
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	3.2980
Acquisition Time	2.4429
Modification Date	2021-05-10T16:54:53
Spectrometer Frequency	399.78
Spectral Width	7204.5
Lowest Frequency	-1198.8
Nucleus	Proton











Parameter	Value
Origin	Varian
Spectrometer	vnmr
Solvent	"cdcl3"
Temperature	20.0
Pulse Sequence	s2pul
Experiment	1D
Number of Scans	16
Receiver Gain	44
Relaxation Delay	1.0000
Pulse Width	0.0000
Acquisition Time	2.5559
Modification Date	2020-09-24T11:50:00
Spectrometer Frequency	399.76
Spectral Width	6410.3
Lowest Frequency	-799.6
Nucleus	1H







Parameter	Value
Origin	Varian
Spectrometer	vnmrS
Solvent	"cdcl3"
Temperature	20.0
Pulse Sequence	s2pul
Experiment	1D
Number of Scans	32
Receiver Gain	50
Relaxation Delay	1.0000
Pulse Width	0.0000
Acquisition Time	2.5559
Modification Date	2021-05-10T22:56:00
Spectrometer Frequency	399.76
Spectral Width	6410.3
Lowest Frequency	-799.4
Nucleus	1H

7.9182
7.8976
7.8564
7.8356
7.4350
7.4145
7.3477
7.3275
7.2601
6.9963
6.9748
6.7124
6.6907

—4.4896
—3.9639
—3.7580

—2.5944
—2.4605



—197.77

—186.92

—159.14

—143.87

—139.35
—138.42
—136.49
—130.47
—130.38
—129.63
—128.76
—127.18
—126.83

—114.06

—77.48
—77.16
—76.84

—55.34



—44.09

—36.10

—26.75

—21.73



Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	"cdcl3"
Temperature	
Experiment	1D
Number of Scans	795
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	4.7316
Acquisition Time	0.6336
Modification Date	2021-05-10T23:21:06
Spectrometer Frequency	100.53
Spectral Width	25252.1
Lowest Frequency	-2573.1
Nucleus	Carbon13




Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	"cdcl3"
Temperature	
Experiment	1D
Number of Scans	8
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	3.2980
Acquisition Time	2.4429
Modification Date	2021-05-10T16:25:37
Spectrometer Frequency	399.78
Spectral Width	7204.5
Lowest Frequency	-1188.8
Nucleus	Proton



7.9381
7.9175
7.5734
7.5535
7.3768
7.3565
7.3128
7.3086
7.2795
7.1867
7.0981
6.9426
6.7208


—4.6016
—3.9999
—3.7669
—2.4764








Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	"cdcl3"
Temperature	
Experiment	1D
Number of Scans	8
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	3.2980
Acquisition Time	2.4429
Modification Date	2021-05-10T16:51:00
Spectrometer Frequency	399.78
Spectral Width	7204.5
Lowest Frequency	-1198.4
Nucleus	Proton








































Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	DMSO
Temperature	
Experiment	1D
Number of Scans	8
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	3.2980
Acquisition Time	2.4429
Modification Date	2021-05-18T17:20:13
Spectrometer Frequency	399.78
Spectral Width	7204.5
Lowest Frequency	-1203.6
Nucleus	Proton






















































































S100
















































Parameter	Value
Origin	Varian
Spectrometer	vnmrs
Solvent	dmso
Temperature	20.0
Pulse Sequence	s2pul
Experiment	1D
Number of Scans	12
Receiver Gain	30
Relaxation Delay	1.0000
Pulse Width	0.0000
Acquisition Time	2.5559
Spectrometer Frequency	399.76
Spectral Width	6410.3
Lowest Frequency	-806.6
Nucleus	1H





10.7388


1.2623
1.2433
1.2243


S117





Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	DMSO
Temperature	
Experiment	1D
Number of Scans	184
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	4.6000
Acquisition Time	0.6336
Modification Date	2021-10-24T18:37:17
Spectrometer Frequency	100.53
Spectral Width	25252.1
Lowest Frequency	-2573.5
Nucleus	Carbon13





































Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	DMSO
Temperature	
Experiment	1D
Number of Scans	8
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	3.2980
Acquisition Time	2.4429
Modification Date	2021-06-02T15:23:01
Spectrometer Frequency	399.78
Spectral Width	9005.8
Lowest Frequency	-2092.2
Nucleus	Proton





Parameter	Value
Origin	JEOL
Spectrometer	ECA
Solvent	DMSO
Temperature	
Experiment	1D
Number of Scans	371
Receiver Gain	
Relaxation Delay	2.0000
Pulse Width	4.7316
Acquisition Time	0.6336
Modification Date	2021-06-02T15:40:16
Spectrometer Frequency	100.53
Spectral Width	31565.7
Lowest Frequency	-5730.7
Nucleus	Carbon13


— 144.2286
 — 141.6533
 — 140.9165
 — 136.7130
 — 130.0054
 ✓ 129.7817
 ✓ 129.2423
 ✓ 128.5133
 ✓ 127.8783
 ✓ 127.2159
 ✓ 127.0522
 ✓ 127.0365
 ✓ 126.5168


— 56.8219

✓ 40.6557
 ✓ 40.4471
 ✓ 40.2387
 ✓ 40.0299
 ✓ 39.8209
 ✓ 39.6116
 ✓ 39.4028

✓ 21.7717
 ✓ 21.4090







**d-acetone
solent blank**

